Loading...

DiaSorin

DB:34D
Snowflake Description

Outstanding track record with excellent balance sheet and pays a dividend.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
34D
DB
€5B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

DiaSorin S.p.A. develops, produces, and commercializes diagnostic tests in various clinical areas for hospital and private testing laboratories in the market of immunodiagnostics and molecular diagnostics. The last earnings update was 107 days ago. More info.


Add to Portfolio Compare Print
34D Share Price and Events
7 Day Returns
-0.1%
DB:34D
2%
DE Medical Equipment
2.2%
DE Market
1 Year Returns
19.5%
DB:34D
23.8%
DE Medical Equipment
-11%
DE Market
34D Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
DiaSorin (34D) -0.1% 6% 6.1% 19.5% 70.8% 143.6%
DE Medical Equipment 2% 5.4% 5.4% 23.8% 78% 182.1%
DE Market 2.2% 2.7% 1.6% -11% 13.6% 6.8%
1 Year Return vs Industry and Market
  • 34D underperformed the Medical Equipment industry which returned 23.8% over the past year.
  • 34D outperformed the Market in Germany which returned -11% over the past year.
Price Volatility
34D
Industry
5yr Volatility vs Market

Value

 Is DiaSorin undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of DiaSorin to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our calculation method for this is changing soon.

Below are the data sources, inputs and calculation used to determine the intrinsic value for DiaSorin.

DB:34D Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:34D
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 9.8%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.4
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.403 (1 + (1- 24%) (0%))
0.403
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.8 * 9.77%)
8.05%

Discounted Cash Flow Calculation for DB:34D using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for DiaSorin is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:34D DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (EUR, Millions) 167.19 175.49 210.00 229.00 249.00
Source Analyst x6 Analyst x6 Analyst x1 Analyst x1 Analyst x1
Present Value
Discounted (@ 8.05%)
154.74 150.33 166.49 168.04 169.11
Present value of next 5 years cash flows €808.71
DB:34D DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= €249.00 × (1 + 0.23%) ÷ (8.05% – 0.23%)
€3,192.38
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= €3,192.38 ÷ (1 + 8.05%)5
€2,168.10
DB:34D Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= €808.71 + €2,168.10
€2,976.81
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €2,976.81 / 54.70
€53.59
DB:34D Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:34D represents 0.98473x of BIT:DIA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.98473x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 54.42 x 0.98473
€53.59
Value per share (EUR) From above. €53.59
Current discount Discount to share price of €83.80
= -1 x (€83.80 - €53.59) / €53.59
-56.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of DiaSorin is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for DiaSorin's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are DiaSorin's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:34D PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in EUR €2.94
BIT:DIA Share Price ** BIT (2019-02-21) in EUR €85.1
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 29.27x
Germany Market PE Ratio Median Figure of 420 Publicly-Listed Companies 18.09x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of DiaSorin.

DB:34D PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BIT:DIA Share Price ÷ EPS (both in EUR)

= 85.1 ÷ 2.94

28.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DiaSorin is good value based on earnings compared to the DE Medical Equipment industry average.
  • DiaSorin is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does DiaSorin's expected growth come at a high price?
Raw Data
DB:34D PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 28.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
9.5%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.8x
Germany Market PEG Ratio Median Figure of 277 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

DB:34D PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 28.92x ÷ 9.5%

3.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DiaSorin is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on DiaSorin's assets?
Raw Data
DB:34D PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in EUR €13.83
BIT:DIA Share Price * BIT (2019-02-21) in EUR €85.1
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.07x
Germany Market PB Ratio Median Figure of 565 Publicly-Listed Companies 1.8x
DB:34D PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BIT:DIA Share Price ÷ Book Value per Share (both in EUR)

= 85.1 ÷ 13.83

6.15x

* Primary Listing of DiaSorin.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DiaSorin is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess DiaSorin's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. DiaSorin has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is DiaSorin expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is DiaSorin expected to grow at an attractive rate?
  • DiaSorin's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • DiaSorin's earnings growth is positive but not above the Germany market average.
  • DiaSorin's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:34D Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:34D Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 9.5%
DB:34D Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 7.7%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:34D Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:34D Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 996 309 269 2
2022-12-31 911 270 227 4
2021-12-31 854 250 205 5
2020-12-31 788 238 181 9
2019-12-31 727 225 169 9
2018-12-31 672 222 154 9
DB:34D Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-09-30 663 175 161
2018-06-30 649 179 154
2018-03-31 644 154 145
2017-12-31 637 167 140
2017-09-30 625 174 125
2017-06-30 622 174 125
2017-03-31 602 183 121
2016-12-31 569 166 112
2016-09-30 544 160 111
2016-06-30 520 151 106
2016-03-31 506 138 102
2015-12-31 499 138 100

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • DiaSorin's earnings are expected to grow by 9.5% yearly, however this is not considered high growth (20% yearly).
  • DiaSorin's revenue is expected to grow by 7.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:34D Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from DiaSorin Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:34D Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.80 4.80 4.80 1.00
2022-12-31 3.99 4.35 3.63 2.00
2021-12-31 3.66 3.87 3.44 2.00
2020-12-31 3.28 3.46 3.12 8.00
2019-12-31 3.04 3.16 2.90 8.00
2018-12-31 2.77 2.86 2.64 7.00
DB:34D Past Financials Data
Date (Data in EUR Millions) EPS *
2018-09-30 2.94
2018-06-30 2.78
2018-03-31
2017-12-31 2.54
2017-09-30
2017-06-30 2.28
2017-03-31
2016-12-31 2.05
2016-09-30
2016-06-30 1.92
2016-03-31
2015-12-31 1.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • DiaSorin is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess DiaSorin's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
DiaSorin has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has DiaSorin performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare DiaSorin's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • DiaSorin's year on year earnings growth rate has been positive over the past 5 years.
  • DiaSorin's 1-year earnings growth exceeds its 5-year average (28.4% vs 14.5%)
  • DiaSorin's earnings growth has exceeded the DE Medical Equipment industry average in the past year (28.4% vs -2.1%).
Earnings and Revenue History
DiaSorin's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from DiaSorin Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:34D Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 662.89 160.98 197.05 44.73
2018-06-30 649.40 154.26 192.24 44.29
2018-03-31 644.49 145.28 189.35 45.13
2017-12-31 637.49 139.88 188.35 43.63
2017-09-30 624.61 125.38 185.32 43.12
2017-06-30 622.35 124.91 183.50 42.59
2017-03-31 602.31 120.58 178.02 40.72
2016-12-31 569.31 112.38 170.12 37.72
2016-09-30 544.08 111.06 163.64 34.15
2016-06-30 520.27 105.50 158.04 30.19
2016-03-31 506.04 102.49 154.93 27.29
2015-12-31 499.18 100.42 154.10 26.16
2015-09-30 486.35 94.76 150.76 25.37
2015-06-30 472.14 92.92 147.61 25.29
2015-03-31 455.50 86.99 143.77 25.11
2014-12-31 443.77 84.07 140.28 24.99
2014-09-30 436.72 83.55 139.10 24.79
2014-06-30 431.90 82.18 136.74 24.14
2014-03-31 434.93 82.30 137.16 23.87
2013-12-31 434.85 83.03 136.03 23.95
2013-09-30 432.54 81.50 133.95 23.76
2013-06-30 432.80 82.86 133.73 23.82
2013-03-31 433.95 85.46 131.51 23.93
2012-12-31 433.76 87.40 131.12 23.39
2012-09-30 432.86 88.84 129.56 23.08
2012-06-30 433.56 88.46 128.32 22.52
2012-03-31 434.25 93.35 127.55 21.74

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • DiaSorin has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • DiaSorin used its assets more efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • DiaSorin has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess DiaSorin's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
DiaSorin has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is DiaSorin's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up DiaSorin's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • DiaSorin is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • DiaSorin's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of DiaSorin's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • DiaSorin has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from DiaSorin Company Filings, last reported 4 months ago.

DB:34D Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 756.80 0.00 128.80
2018-06-30 624.82 13.89 117.57
2018-03-31 771.60 0.00 168.60
2017-12-31 741.96 24.01 173.31
2017-09-30 699.50 0.00 113.30
2017-06-30 662.43 39.80 129.03
2017-03-31 693.50 0.00 114.10
2016-12-31 663.39 59.31 130.47
2016-09-30 616.76 64.12 110.68
2016-06-30 588.95 67.30 73.22
2016-03-31 602.00 2.30 292.14
2015-12-31 587.16 2.44 270.36
2015-09-30 552.18 2.22 233.82
2015-06-30 531.41 2.91 198.89
2015-03-31 544.19 4.09 224.31
2014-12-31 483.57 3.48 169.82
2014-09-30 459.12 3.36 148.01
2014-06-30 426.89 3.53 110.76
2014-03-31 434.20 7.19 132.21
2013-12-31 414.14 7.18 105.11
2013-09-30 395.59 8.36 92.36
2013-06-30 379.60 8.65 67.51
2013-03-31 390.61 12.82 85.41
2012-12-31 365.13 12.61 104.60
2012-09-30 394.70 16.84 91.81
2012-06-30 376.28 17.33 69.84
2012-03-31 373.60 22.51 80.63
  • DiaSorin has no debt.
  • DiaSorin has no debt compared to 5 years ago when it was 2.1%.
  • DiaSorin has no debt, it does not need to be covered by operating cash flow.
  • DiaSorin has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess DiaSorin's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. DiaSorin has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is DiaSorin's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1%
Current annual income from DiaSorin dividends. Estimated to be 1.35% next year.
If you bought €2,000 of DiaSorin shares you are expected to receive €20 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • DiaSorin's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.52%).
  • DiaSorin's dividend is below the markets top 25% of dividend payers in Germany (3.91%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:34D Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 332 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:34D Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 1.41 2.00
2021-12-31 1.28 2.00
2020-12-31 1.15 8.00
2019-12-31 1.07 8.00
2018-12-31 0.98 8.00
DB:34D Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2018-03-07 0.850 1.029
2017-05-15 0.800 1.090
2016-04-07 0.650 1.149
2016-03-09 0.650 1.367
2015-03-30 0.600 1.394
2015-03-03 0.600 1.551
2014-04-01 0.550 1.761
2014-03-06 0.550 1.779
2013-03-25 0.500 1.570
2013-03-08 0.500 1.853
2012-08-06 0.460 1.680
2012-08-03 0.460 1.860
2012-03-30 0.460 2.136
2012-03-12 0.460 2.178
2011-03-16 0.400 1.513
2011-02-14 0.400 1.233
2010-04-09 0.200 0.644
2009-04-14 0.120 0.557
2009-02-23 0.100 0.603

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of DiaSorin's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.5x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.9x coverage).
X
Income/ dividend checks
We assess DiaSorin's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can DiaSorin afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. DiaSorin has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of DiaSorin's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carlo Rosa
COMPENSATION €1,330,000
AGE 52
TENURE AS CEO 13.1 years
CEO Bio

Mr. Carlo Rosa has been the Chief Executive Officer of DiaSorin S.p.A. since 2006 and has been its General Manager since April 27, 2010 also its Executive Director since March 26, 2007. In 2001, Mr. Rosa led a management buy out with four other managers and a group of financial investors to buy DiaSorin from the previous owner, American Standard Inc. As a result, he became the Chief Operating Officer of DiaSorin until 2006. In 1990, he moved to New York to work at the Public Health Research Institute on a project aimed at the development of a new innovative product for diagnosing Hepatitis CV infections. In 1992, he joined Incstar Corporation, (MN) USA, an American Public Company and worked in the R&D department to lead a project in joint venture with Akzo Nobel. Then he held different positions both in the R&D and the Strategic Marketing departments until he took the role of Director of the Infectious Disease Business Unit. In 1998, he moved back to Italy to assume the role of Director of European S&M for DiaSorin Spa. Mr. Rosa serves as the Director at DiaSorin Inc. In 2014, he was nominated as Vice Chairman of Alisei, a consortium of private and public Italian entities intended to promote the development of Life Science in Italy. Mr. Rosa graduated in 1990 in Chemistry from the University of Torino summa cum laude.

CEO Compensation
  • Carlo's compensation has been consistent with company performance over the past year.
  • Carlo's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the DiaSorin management team in years:

3.1
Average Tenure
53.5
Average Age
  • The tenure for the DiaSorin management team is about average.
Management Team

Carlo Rosa

TITLE
CEO, GM & Executive Director
COMPENSATION
€1M
AGE
52
TENURE
13.1 yrs

Chen Even

TITLE
Chief Commercial Officer & Executive Director
COMPENSATION
€663K
AGE
55
TENURE
3.1 yrs

Piergiorgio Pedron

TITLE
Corporate Accounting Documents Officer
AGE
47
TENURE
2.8 yrs

Riccardo Fava

TITLE
Senior Director of Investor Relations & Corporate Communication

Marco Minolfo

TITLE
Manager of the Corporate Legal Affairs Department

Stefano Ronchi

TITLE
Senior Corporate Vice President of Human Resources
AGE
58
Board of Directors Tenure

Average tenure and age of the DiaSorin board of directors in years:

7.3
Average Tenure
53.5
Average Age
  • The tenure for the DiaSorin board of directors is about average.
Board of Directors

Gustavo Denegri

TITLE
Chairman
COMPENSATION
€400K
AGE
81
TENURE
8.8 yrs

Carlo Rosa

TITLE
CEO, GM & Executive Director
COMPENSATION
€1M
AGE
52
TENURE
11.9 yrs

Michele Denegri

TITLE
Deputy Chairman
COMPENSATION
€150K
AGE
49
TENURE
5.8 yrs

Chen Even

TITLE
Chief Commercial Officer & Executive Director
COMPENSATION
€663K
AGE
55
TENURE
11.9 yrs

Franco Moscetti

TITLE
Independent Director
COMPENSATION
€55K
AGE
67
TENURE
11.9 yrs

Giuseppe Alessandria

TITLE
Lead Independent Director
COMPENSATION
€45K
AGE
76
TENURE
5.8 yrs

Monica Mannino

TITLE
Chairman of Board of Statutory Auditors
AGE
49
TENURE
2.8 yrs

Enrico Amo

TITLE
Non-Executive Director
COMPENSATION
€35K
AGE
62
TENURE
11.9 yrs

Roberta Somati

TITLE
Independent Director
COMPENSATION
€35K
AGE
49
TENURE
5.8 yrs

Stefano Altara

TITLE
Non-Executive Director
COMPENSATION
€35K
AGE
51
TENURE
4.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess DiaSorin's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. DiaSorin has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Map
Description

DiaSorin S.p.A. develops, produces, and commercializes diagnostic tests in various clinical areas for hospital and private testing laboratories in the market of immunodiagnostics and molecular diagnostics. It offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; stool diagnostics; autoimmunity; and cardiac and brain damages. The company’s immunodiagnostics systems include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; EVOlyzer 2-150/8 with disposable tips to automate microplate based assays; and ETI Max 3000, an automated microtiter plate analyzer. It also offers molecular diagnostic products LIAISON MDX a thermocycler; and LIAISON IAM, an instrument for amplification of nucleic acids, as well as kits, PCR master mixes, primer pairs, and molecular controls for monitoring oncology and infectious diseases. The company sells its products directly, as well as through an international network of independent distributors in Europe, Africa, North Americam Central America, South America, and the Asia Pacific. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.

Details
Name: DiaSorin S.p.A.
34D
Exchange: DB
Founded: 1968
€4,666,180,571
54,703,172
Website: http://www.diasorin.com
Address: DiaSorin S.p.A.
Via Crescentino,
Saluggia,
Vercelli, 13040,
Italy
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BIT DIA Common Shares Borsa Italiana IT EUR 19. Jul 2007
OTCPK DSRL.F Common Shares Pink Sheets LLC US USD 19. Jul 2007
DB 34D Common Shares Deutsche Boerse AG DE EUR 19. Jul 2007
LSE 0GZX Common Shares London Stock Exchange GB EUR 19. Jul 2007
BATS-CHIXE DIAM Common Shares BATS 'Chi-X Europe' GB EUR 19. Jul 2007
Number of employees
Current staff
Staff numbers
1,879
DiaSorin employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/22 21:27
End of day share price update: 2019/02/21 00:00
Last estimates confirmation: 2019/02/01
Last earnings filing: 2018/11/07
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.